Rite Aid to sell 1,000 pharmacy assets to CVS, Walgreens and others

Reuters
16 May
UPDATE 5-Rite Aid to sell 1,000 pharmacy assets to CVS, Walgreens and others

Adds context, CEO comment on jobs in paragraphs 4 and 7-9

By Sabrina Valle

May 15 (Reuters) - Bankrupt U.S. pharmacy chain Rite Aid on Thursday said it agreed to sell pharmacy assets from more than 1,000 store locations in separate transactions to CVS Pharmacy, Walgreens, Albertsons, Kroger and Giant Eagle, among others.

CVS Pharmacy will buy and operate many Rite Aid and Bartell Drugs stores in Washington, Oregon and Idaho, Rite Aid said in a filing.

Rite Aid stores will remain open, and customers can continue to use pharmacy services, including prescription refills and immunizations, without interruption, it said.

The sale includes prescription files and other goods, a person familiar with the agreements said.

Walgreens declined to comment. The other bidders did not immediately respond to requests for comment.

Earlier this month, Rite Aid filed for bankruptcy for the second time in less than two years, after poor performance in its retail business made it difficult for the company to maintain sufficient cash flow and restock its retail inventory.

The company has received court approval to pursue a rapid-fire sale of its pharmacy business. Rite Aid is scheduled to conduct a hearing to approve the sales on May 21. The sales will remain subject to regulatory notices and approvals.

The Pennsylvania-based company entered bankruptcy with over $2 billion in debt and has warned employees about likely job cuts. Rite Aid Chief Executive Matt Schroeder said on Thursday the company would try to preserve jobs during the transition.

"These agreements ensure our pharmacy customers will experience a smooth transition while preserving jobs for some of our valued team members," Schroeder said in a note.

Bloomberg had previously reported on CVS' bid.

(Reporting by Sabrina Valle in New York and Christy Santhosh in Bengaluru; Additional reporting by Dietrich Knauth and Juveria Tabassum; Editing by Leroy Leo, Cynthia Osterman and Tom Hogue)

((Sabrina.valle@tr.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10